SITC 2023 | Sip-T treatment for metastatic castration-resistant prostate cancer

Russell Pachynski, MD, Washington University School of Medicine, St Louis, MO, outlines future plans to progress his research in Sipuleucel-T (sip-T) plus IL-15 treatment for metastatic castration-resistant prostate cancer (mCRPC). Having conducted this trial previously with IL-7 with no significant effect on overall survival, Dr Pachynski assures that IL-15’s data is more promising for use in this context. With several IL-15 superagonists in development, Dr Pachynski plans to test these in early Phase trials in conjunction with sip-T, with the aim of seeing an increase in tumor infiltrating lymphocytes (TILs) and better overall immune responses in patients with mCRPC. This interview took place at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.